Agios Pharmaceuticals (NASDAQ:AGIO) Shares Pass Below 200 Day Moving Average – Should You Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $29.87 and traded as low as $27.75. Agios Pharmaceuticals shares last traded at $28.21, with a volume of 757,913 shares changing hands.

Analysts Set New Price Targets

AGIO has been the subject of a number of research reports. Truist Financial dropped their price target on Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. JPMorgan Chase & Co. increased their price target on Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Monday, April 6th. Citigroup increased their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. Finally, Bank of America lowered their target price on Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $41.56.

Agios Pharmaceuticals Trading Up 0.1%

The firm has a market capitalization of $1.68 billion, a P/E ratio of -3.89 and a beta of 0.58. The company has a 50-day moving average of $29.59 and a 200-day moving average of $29.87.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.81) by $0.12. The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.Agios Pharmaceuticals’s quarterly revenue was up 137.7% on a year-over-year basis. Research analysts predict that Agios Pharmaceuticals, Inc. will post -6.19 EPS for the current year.

Insider Activity

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 2,940 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $102,047.40. Following the completion of the sale, the insider directly owned 80,277 shares in the company, valued at approximately $2,786,414.67. This trade represents a 3.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the sale, the chief financial officer owned 54,998 shares of the company’s stock, valued at approximately $1,908,980.58. The trade was a 5.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 15,582 shares of company stock worth $520,405. 5.40% of the stock is owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth about $25,000. Assetmark Inc. grew its holdings in Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 362 shares during the period. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals during the 1st quarter worth about $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth about $49,000. Finally, Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $79,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.